Matchpoint Therapeutics is using small molecules and covalent chemistry to develop novel precision medicines to treat immune diseases. Covalency offers unique pharmacological benefits due to the irreversible binding nature of the covalent medicine with its protein target. Matchpoint is using chemoproteomic screens to detect allosteric, transient and cryptic binding pockets of protein targets that can be targeted by covalent molecules. The screens are part of Matchpoint’s Advanced Covalent Exploration (ACE) platform that employs machine learning to extract insights from extensive data sets such as the chemoproteomics screens and publicly available data to prioritize targets of interest and guide medicinal chemistry of the covalent screening library.

<p>Claim company profile to add description to this page.</p>


Matchpoint Therapeutics

Founded: 2021
Location: Cambridge, MA
Employee range: 11 - 50
Clinical stage: RD
Product link: https://matchpointtx.com/#approach
Funding: $70M A Oct 2022; $30M seed Nov 2021
Investors: Atlas Venture, Access Biotechnology, Vertex Ventures HC, Digitalis Ventures, Alexandria Venture Investments

Short description:

Drug notes:

Long description:

Jobs: